Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21079742 | 0.98 | KDM1A (0.30) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL21079740 | 0.98 | KDM1A (0.30) | KDM1AMAOB | |
| SCHEMBL110926 | 0.89 | — | — | |
| SCHEMBL2606652 | 0.81 | — | — | |
| SCHEMBL17675557 | 0.81 | EIF2AK4 (0.34) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8060559 | 0.79 | L3MBTL1 (0.36) | NPC1RAB9ASMN1; SMN2 | |
| Formic Acid SCHEMBL28961942 | 0.78 | CHRNA4 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16992452 | 0.76 | SLC18A3 (0.41) | — | |
| SCHEMBL871800 | 0.73 | NPC1 (0.41) | NPC1RAB9A | |
| SCHEMBL657159 | 0.73 | CHRM1 (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | KDM1A 2214/4885MAOB 90/4885SMYD3 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.